Ob/Gyn Panel Unanimously Supports Adhesion-Prevention Product Approval
This article was originally published in The Gray Sheet
Executive Summary
Baxter's biosurgery business stands to gain from an FDA advisory panel's unanimous support for a product designed to prevent a serious side effect of certain surgical procedures. But limitations recommended for the label could curb some of the market potential if adopted by the agency in its final approval decision